DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
Top Cited Papers
Open Access
- 9 January 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 96 (2), 189-195
- https://doi.org/10.1038/sj.bjc.6603515
Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.Keywords
This publication has 39 references indexed in Scilit:
- 5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting AgentClinical Cancer Research, 2006
- Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast CancerJournal of Clinical Oncology, 2006
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I StudyJournal of Clinical Oncology, 2005
- Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursEuropean Journal Of Cancer, 2005
- Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized VolumeJournal of Clinical Oncology, 2005
- Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over timeJournal of Magnetic Resonance Imaging, 2004
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance ImagingJournal of Clinical Oncology, 2003
- Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated DailyJournal of Clinical Oncology, 2002